Data Privacy at Ranbaxy
Yesterday, Malvinder Singh, CEO of Ranbaxy announced acquisition of Terapia, the sixth largest generics drug maker in Romania. Intelligent move, I must say. However, he declined to give profit numbers for terapia to protect the privacy of the deal details.
Let me throw a stone in dark dark skies, and make a guess:
1. Malvinder Singh disclosed that Ranbaxy acquired a 96.7% stake in Terapia for $324 million. Ranbaxy valued the company at 11.6 times the EBIDTA. That makes Terapia worth $335.06 million, and dividing it by 11.6 gives a profit figure of $28.8 million.
2. He also disclosed that profit margins of Terapia was in excess of 35% on an annual sale of $80 million. 35% of $80 million is $28 million.
Probably Ranbaxy needs stronger data protection measures. Ever heard of BS7799. Sorry for leaking your secrets Malvinder.
Tags: Ranbaxy, Terapia
Yesterday, Malvinder Singh, CEO of Ranbaxy announced acquisition of Terapia, the sixth largest generics drug maker in Romania. Intelligent move, I must say. However, he declined to give profit numbers for terapia to protect the privacy of the deal details.
Let me throw a stone in dark dark skies, and make a guess:
1. Malvinder Singh disclosed that Ranbaxy acquired a 96.7% stake in Terapia for $324 million. Ranbaxy valued the company at 11.6 times the EBIDTA. That makes Terapia worth $335.06 million, and dividing it by 11.6 gives a profit figure of $28.8 million.
2. He also disclosed that profit margins of Terapia was in excess of 35% on an annual sale of $80 million. 35% of $80 million is $28 million.
Probably Ranbaxy needs stronger data protection measures. Ever heard of BS7799. Sorry for leaking your secrets Malvinder.
Tags: Ranbaxy, Terapia
posted by Rohit at 9:58 PM
0 Comments:
Post a Comment
<< Home